Ruhr University
- Address
- lock Available on a paid plan
Neurology and Pain Research
At Ruhr University in Bochum, the Klinik für Neurologie is running studies focused on nervous system diseases and pathological pain conditions. The research mainly explores chronic pain linked to nerve damage, with the goal of evaluating new ways to improve symptom control and treatment effectiveness.
- Chronic pain due to diabetic polyneuropathy
- Chronic pain after traumatic or post-operative peripheral neuropathy
- Chronic pain from central neuropathy
- Chronic back pain
These trials are examining whether add-on therapies can better relieve persistent pain and support people living with long-term neurological discomfort.
Autoimmune and Neuroinflammatory Disorders
Another major area of research at this educational institution is immune system disease research, especially conditions that affect the brain and nervous system. The studies are designed to assess new treatment options and their safety in serious neuroinflammatory illness.
- Autoimmune encephalitis
- Multiple sclerosis
This work includes testing therapies for severe autoimmune encephalitis and evaluating new formulations of treatment for multiple sclerosis, with the aim of improving care and expanding practical options for patients.
Movement Disorder Research
The site is also involved in clinical research on Parkinson’s disease, reflecting its broader focus on nervous system diseases. These studies are intended to evaluate the effectiveness of new approaches for early-stage illness and to support better management of disease progression.
- Early-stage Parkinson’s disease
By studying potential therapies in people with early symptoms, the team aims to improve treatment strategies before the condition advances further.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1F. Hoffmann-La Roche AG1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Apurano Pharmaceuticals GmbH4trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ruhr University
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase II, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients with Multiple Sclerosis | F. Hoffmann-La Roche AG | Phase II | Not Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adezunap | 4 | Unknown | 2023-11-02 | 2023-11-02 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.